Johnson & Johnson (JNJ) News

Johnson & Johnson (JNJ): $153.89

1.51 (+0.99%)

POWR Rating

Component Grades













Filter JNJ News Items

JNJ News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

JNJ News Highlights

  • For JNJ, its 30 day story count is now at 22.
  • Over the past 9 days, the trend for JNJ's stories per day has been choppy and unclear. It has oscillated between 2 and 8.
  • AMP, TALK and ADD are the most mentioned tickers in articles about JNJ.

Latest JNJ News From Around the Web

Below are the latest news stories about JOHNSON & JOHNSON that investors may wish to consider to help them evaluate JNJ as an investment opportunity.

26 Companies that Donate to Nonprofits

In this piece, we will take a look at the 26 companies that donate to nonprofits. For more companies, head on over to 5 Companies that Donate to Nonprofits. Corporate greed is always a popular topic in the press. And, firms are to blame for some extent as well. There are well known examples of […]

Yahoo | March 16, 2023

15 Best US Stocks for Foreigners

In this article, we take a look at 15 best US stocks for foreigners. If you want to see more best US stocks for foreigners, go directly to 5 Best US Stocks for Foreigners. Given the United States has the largest economy in the world, many foreigners invest in American stocks. Furthermore, many leading American companies […]

Yahoo | March 16, 2023

10 Best Stocks to Buy for Medium Term

In this article, we will be taking a look at the 10 best stocks to buy for medium term. To skip our detailed analysis of the current stock market dynamics, you can go directly to see the 5 Best Stocks to Buy for Medium Term. While some investors prefer to hold long-term positions in the […]

Yahoo | March 16, 2023

CMS releases 'bombshell' guidance draft of Medicare drug price negotiations

Medicare issues draft guidance for drug price negotiation

Yahoo | March 16, 2023

10 Stocks ChatGPT Says Will Make Me Rich in 10 Years

In this article, we will be taking a look at 10 stocks recommended by ChatGPT. To skip our detailed analysis of ChatGPT and developments in artificial intelligence, you can go directly to see the 5 Stocks ChatGPT Says Will Make Me Rich in 10 Years. One of the biggest developments in artificial intelligence (AI) seen […]

Yahoo | March 16, 2023

7 Blue-Chip Stocks to Buy and Hold for Decades

So, what are the best blue-chip stocks to buy and hold for the coming decades?

Thomas Niel on InvestorPlace | March 15, 2023

3 Blue-Chip Dividend Stocks to Buy on the Dip Now

In times of uncertainty, investors want companies they can count on.

Bret Kenwell on InvestorPlace | March 15, 2023

Johnson & Johnson to Host Investor Conference Call on First-Quarter Results

NEW BRUNSWICK, N.J., March 15, 2023--Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, April 18th to review first-quarter results. Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Jessica Moore, Vice President, Investor Relations will host the call. The question and answer portion of the call will also include additional members of Johnson & Johnson’s executive team.

Yahoo | March 15, 2023

Johnson & Johnson's Experimental Dengue Pill Shows Efficacy In Animal Studies

New data published in the journal Nature shows that Johnson & Johnson's (NYSE: JNJ) experimental dengue pill proved effective against all four virus types in mice and prevented infection from two types in monkeys. The first-in-class antiviral, shown to be safe and well tolerated in Phase 1 first-in-human clinical study, is now progressing into Phase 2 clinical studies to prevent and treat dengue. Reuters writes that early animal results add hope for what could become the first antiviral treatmen

Yahoo | March 15, 2023

Protagonist Therapeutics Touts Positive Data From Bone Marrow Disorder Study

Protagonist Therapeutics Inc (NASDAQ: PTGX) announced topline results from the blinded, placebo-controlled, randomized withdrawal portion of REVIVE of rusfertide for polycythemia vera, causing the bone marrow to make too many red blood cells. Subjects receiving rusfertide achieved highly statistically significant improvements versus placebo in the primary endpoint. More subjects receiving rusfertide during the blinded randomized withdrawal portion of the REVIVE study were responders compared wit

Yahoo | March 15, 2023

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.5947 seconds.